Introduction
============

Coronary artery disease (CAD) and myocardial infarction (MI) are serious clinical conditions that remain the leading causes of mortality in the United States ([@b1-ijmm-42-05-2415]). Disease prevention is an important strategy for reducing the overall burden of these conditions, with the identification of biomarkers for disease risk being key for risk prediction and for potential intervention to reduce the chance of future coronary events.

In addition to conventional risk factors for CAD and MI, including hypertension, diabetes mellitus, and dyslipidemia, the importance of genetic factors has been highlighted ([@b2-ijmm-42-05-2415]). The heritability of CAD has been estimated to be 40-60% on the basis of family and twin studies ([@b2-ijmm-42-05-2415],[@b3-ijmm-42-05-2415]). Genome-wide association studies (GWASs) in European-ancestry populations ([@b4-ijmm-42-05-2415]-[@b10-ijmm-42-05-2415]), African Americans ([@b11-ijmm-42-05-2415]), or Han Chinese ([@b12-ijmm-42-05-2415],[@b13-ijmm-42-05-2415]) have identified various genes and loci that confer susceptibility to CAD or MI. A meta-analysis of GWASs for CAD among European-ancestry populations, which included low-frequency variants, identified 202 independent genetic variants at 129 loci with a false discovery rate of \<5% ([@b14-ijmm-42-05-2415]). These genetic variants together account for \~28% of the heritability of CAD, showing that genetic susceptibility to this condition is largely determined by common variants with small effect sizes ([@b2-ijmm-42-05-2415],[@b14-ijmm-42-05-2415]). A more recent meta-analysis for CAD in European-ancestry populations identified 304 independent genetic variants with a false discovery rate of \<5%, with these variants explaining 21.2% of CAD heritability ([@b15-ijmm-42-05-2415]). Although several single nucleotide polymorphisms (SNPs) have been found to be significantly associated with MI in Japanese individuals ([@b16-ijmm-42-05-2415],[@b17-ijmm-42-05-2415]), genetic variants that contribute to susceptibility to MI in the Japanese population remain to be fully elucidated.

Hypertension is a complex multifactorial disorder that results from an interaction between genetic background and both lifestyle and environmental factors ([@b18-ijmm-42-05-2415]). The heritability of hypertension has been estimated to be 84% and that of systolic blood pressure (BP) and diastolic BP has been estimated to be 53 and 49%, respectively ([@b19-ijmm-42-05-2415]). As hypertension is a major risk factor for CAD and stroke ([@b20-ijmm-42-05-2415]), personalized prevention of hypertension is an important public health goal.

GWASs have implicated various loci and genes as influencing BP or conferring susceptibility to hypertension in populations in Europe ([@b6-ijmm-42-05-2415],[@b21-ijmm-42-05-2415]-[@b24-ijmm-42-05-2415]) and African ([@b25-ijmm-42-05-2415],[@b26-ijmm-42-05-2415]) and in individuals from East Asia ([@b27-ijmm-42-05-2415]). A trans-ancestry GWAS in individuals of European and East or South Asian ancestry identified 12 loci associated with BP ([@b28-ijmm-42-05-2415]). A previous trans-ancestry meta-analysis in individuals of European and South Asian ancestry identified 30 susceptibility loci for BP or hypertension ([@b29-ijmm-42-05-2415]). Although an SNP in *ADD2* was shown to be a susceptibility locus for hypertension in Japanese individuals ([@b30-ijmm-42-05-2415]), genetic variants that confer susceptibility to this condition in Japanese individuals await definitive identification.

Chronic kidney disease (CKD) is also a global public health problem, with affected individuals being at increased risk for end-stage renal disease (ESRD), cardiovascular disease and premature death ([@b31-ijmm-42-05-2415],[@b32-ijmm-42-05-2415]). The identification of biomarkers for CKD risk is important to prevent progression to ESRD and to reduce the chance of future cardiovascular adverse events ([@b33-ijmm-42-05-2415]). In addition to conventional risk factors for CKD, including diabetes mellitus and hypertension ([@b34-ijmm-42-05-2415]), studies have shown the importance of genetic factors in renal function and in the development of CKD ([@b35-ijmm-42-05-2415]). The heritability of glomerular filtration rate for creatinine clearance has been estimated to be 52% ([@b36-ijmm-42-05-2415]).

GWASs have implicated several genes and loci in renal function or predisposition to CKD or ESRD in populations of European ([@b37-ijmm-42-05-2415]-[@b42-ijmm-42-05-2415]) or African ([@b43-ijmm-42-05-2415]) ancestry, and in renal function-related traits in East Asian populations ([@b44-ijmm-42-05-2415]). A meta-analysis of GWASs in European populations identified 53 loci that were significantly associated with estimated glomerular filtration rate (eGFR) ([@b45-ijmm-42-05-2415]). Although several SNPs have been shown to be associated with renal function in East Asian populations ([@b44-ijmm-42-05-2415]), genetic variants that contribute to predisposition to CKD in the Japanese population remain to be fully elucidated.

A previous study of monozygotic and dizygotic twins found that CAD-associated mortality rate at younger ages was significantly influenced by genetic factors in men and women, whereas the genetic effect was less pronounced at older ages ([@b46-ijmm-42-05-2415]). A family history of MI is also more apparent in individuals with early-onset MI compared with those with late-onset MI, suggestive of increased heritability in the former individuals ([@b47-ijmm-42-05-2415],[@b48-ijmm-42-05-2415]). Similar to early-onset MI, early-onset forms of hypertension ([@b49-ijmm-42-05-2415]) and CKD ([@b35-ijmm-42-05-2415]) have been found to have a strong genetic component. As the genetic contribution may be higher in early-onset than in late-onset MI, hypertension and CKD, the statistical power of genetic association studies may be increased by focusing on subjects with early-onset disease ([@b2-ijmm-42-05-2415],[@b35-ijmm-42-05-2415],[@b49-ijmm-42-05-2415]).

In the present study, exome-wide association studies (EWASs) for MI, hypertension, and CKD were performed with the use of human exome array-based genotyping methods in order to identify genetic variants that confer susceptibility to these conditions in Japanese individuals. To increase the statistical power of the EWASs, subjects with early-onset disease were examined.

Materials and methods
=====================

Study subjects
--------------

In our previous EWASs, the median (mean) ages of subjects with MI, hypertension, and CKD were 67 (67.0), 68 (67.2), and 70 (69.9) years, respectively ([@b50-ijmm-42-05-2415]-[@b52-ijmm-42-05-2415]). Therefore patients with an age of ≤65 years were defined as individuals with early-onset forms of these conditions in the present study. A total of 8,093 Japanese individuals aged ≤65 years (subjects with MI, hypertension, or CKD and corresponding controls) was enrolled in the present study. In the EWASs for MI, hypertension, and CKD, 6,926 individuals (1,152 subjects with MI, 5,774 controls), 8,080 individuals (3,444 subjects with hypertension, 4,636 controls), and 2,556 individuals (1,051 subjects with CKD, 1,505 controls) were examined, respectively. The individuals were recruited as those who visited outpatient clinics or were admitted to participating hospitals in Japan (Gifu Prefectural Tajimi Hospital, Tajimi; Gifu Prefectural General Medical Center, Gifu; Japanese Red Cross Nagoya First Hospital, Nagoya, Japan; Northern Mie Medical Center Inabe General Hospital, Inabe, Japan; and Hirosaki University Hospital and Hirosaki Stroke and Rehabilitation Center, Hirosaki, Japan) due to the presence of various symptoms or for an annual health checkup between 2002 and 2014, or who were community-dwelling individuals recruited to a population-based cohort study in Inabe between 2010 and 2014 ([@b53-ijmm-42-05-2415]).

For the MI study, the diagnosis of MI was based on typical electrocardiographic changes and on increases in the serum activity of creatine kinase (MB isozyme) and in the serum concentration of troponin T. The diagnosis was confirmed by identification of the responsible stenosis in any of the major coronary arteries or in the left main trunk by coronary angiography. The control individuals had no history of MI, CAD, aortic aneurysm, or peripheral artery disease; of ischemic or hemorrhagic stroke; or of other atherosclerotic, thrombotic, embolic, or hemorrhagic disorders. Although certain control individuals had conventional risk factors for MI, including hypertension, diabetes mellitus, dyslipidemia, and CKD, they did not have cardiovascular complications.

In the hypertension study, the subjects with hypertension either had a systolic BP of ≥140 mmHg or diastolic BP of ≥90 mmHg (or both), or had taken antihypertensive medication. Individuals with severe valvular heart disease, congenital malformations of the heart or vessels, renal or endocrinologic diseases that cause secondary hypertension, or drug-induced hypertension were excluded from the study. The control individuals had a systolic BP of \<140 mmHg and diastolic BP of \<90 mmHg and no history of hypertension or of taking antihypertensive medication. BP was measured at least twice by a skilled physician or nurse, with subjects having first rested in the sitting position for \>5 min.

For the CKD study, glomerular filtration rate was estimated with the use of the simplified prediction equation derived from a modified version of that described in the Modification of Diet in Renal Disease Study, as suggested by the Japanese Society of Nephrology ([@b54-ijmm-42-05-2415]): eGFR (ml min^−1^ 1.73 m^−2^) = 194 × \[age (years)\] ^−0.287^ × \[serum creatinine (mg/dl)\] ^−1.094^ × \[0.739 if female\]. The National Kidney Foundation-Kidney Disease Outcomes Quality Initiative guidelines recommend a diagnosis of CKD if eGFR is \<60 ml min^−1^ 1.73 m^−2^ ([@b55-ijmm-42-05-2415]). Nonlinear relations between eGFR and the risk of adverse events, including mortality, cardiovascular episodes, and hospitalization, have been demonstrated, with an increased risk being associated with an eGFR of \<60 ml min^−1^ 1.73 m^−2^ and the risk markedly increasing further when values fall \<45 ml min^−1^ 1.73 m^−2^ ([@b56-ijmm-42-05-2415]). Therefore, the criterion of an eGFR of \<60 ml min^−1^ 1.73 m^−2^ was used for the diagnosis of CKD. The control individuals for the CKD study had an eGFR of ≥90 ml min^−1^ 1.73 m^−2^ and had no functional or structural abnormalities of the kidneys or a history of renal disease. Although certain control individuals had hypertension, diabetes mellitus, dyslipidemia, or hyperuricemia, they had no renal complications.

A total of 785 subjects with both MI and hypertension and 3,946 controls overlapped between the corresponding studies, as did 324 subjects with both MI and CKD and 1,127 controls, and 750 subjects with both hypertension and CKD and 955 controls.

EWASs
-----

Venous blood (5 or 7 ml) was collected into tubes containing 50 mmol/l ethylenediaminetetraacetic acid (disodium salt), peripheral blood leukocytes were isolated, and genomic DNA was extracted from these cells with the use of a Genomix DNA extraction kit (Talent Srl, Trieste, Italy) or SMITEST EX-R&D kit (Medical & Biological Laboratories, Co., Ltd., Nagoya, Japan). The EWASs for MI (1,152 cases, 5,774 controls), hypertension (3,444 cases, 4,636 controls), and CKD (1,051 cases, 1,505 controls) were performed with the use of a Human Exome-12 v1.2 DNA Analysis BeadChip or Infinium Exome-24 v1.0 BeadChip (Illumina, San Diego, CA, USA). These exome arrays include putative functional exonic variants selected from \~12,000 individual exome and whole-genome sequences. The exonic content consists of \~244,000 SNPs from European, African, Chinese, and Hispanic individuals ([@b57-ijmm-42-05-2415]). SNPs contained in only one of the exome arrays (\~2.6% of all SNPs) were excluded from analysis. Quality control was performed ([@b58-ijmm-42-05-2415]) as follows: i) Genotyping data with a call rate of \<97% were discarded, with the mean call rate for the remaining data being 99.9%; ii) sex specification was checked for each sample, and those for which sex phenotype in the clinical records was inconsistent with genetic sex chromosomes were discarded; iii) duplicate samples and cryptic relatedness were assessed by calculation of identity by descent; all pairs of DNA samples showing an identity by descent of \>0.1875 were inspected and one sample from each pair was excluded; iv) the frequency of heterozygosity for SNPs was calculated for all samples, and those with low or high heterozygosity (\>3 standard deviations from the mean) were discarded; v) SNPs in sex chromosomes or mitochondrial DNA were excluded from the analysis, as were nonpolymorphic SNPs or SNPs with a minor allele frequency of \<1.0%; vi) SNPs with genotype distributions deviating significantly (P\<0.01) from Hardy-Weinberg equilibrium in control individuals were discarded; vii) genotype data were examined for population stratification by principal components analysis ([@b59-ijmm-42-05-2415]), and population outliers were excluded from the analysis. A total of 31,245, 31,276, or 31,514 SNPs passed quality control for the EWASs of MI, hypertension, and CKD, respectively, and these SNPs were subjected to analyses.

Statistical analysis
--------------------

For analysis of the characteristics of the study subjects, quantitative data were compared between subjects with MI, hypertension, or CKD and corresponding controls with an unpaired t-test. Categorical data were compared between the two groups with Pearson\'s χ^2^ test. Allele frequencies were estimated by the gene counting method, and Fisher\'s exact test was applied to identify departure from Hardy-Weinberg equilibrium. In the EWASs, the relation of allele frequencies of each SNP to MI, hypertension, or CKD was examined with Fisher\'s exact test. To compensate for multiple comparisons of genotypes with MI, hypertension, or CKD, Bonferroni\'s correction was applied for statistical significance of association. As 31,245, 31,276, and 31,514 SNPs that passed quality control were examined in the EWASs for MI, hypertension, and CKD, respectively, P\<1.60×10^−6^ (0.05/31,245 and 31,276) for MI and hypertension or P\<1.59×10^−6^ (0.05/31,514) for CKD was considered statistically significant. The inflation factor (λ) was 0.95 for MI, 1.03 for hypertension, and 1.07 for CKD. Multivariable logistic regression analysis was performed with MI as a dependent variable and independent variables included age, sex (0, woman; 1, man), the prevalence of hypertension, diabetes mellitus, and dyslipidemia (0, no history of these conditions; 1, positive history), and the genotype of each SNP. Similar analysis was performed with hypertension as a dependent variable and independent variables of age, sex, and the genotype of each SNP; and with CKD as a dependent variable and independent variables of age, sex, the prevalence of hypertension and diabetes mellitus, and the genotype of each SNP. The genotypes of the SNPs were assessed according to dominant \[0, *AA*; 1, *AB* + *BB* (*A*, major allele; *B*, minor allele)\], recessive (0, *AA* + *AB*; 1, *BB*), and additive genetic models, and the P*-*value, odds ratio, and 95% confidence interval were calculated. Additive models comprised additive 1 (0, *AA*; 1, *AB*; 0, *BB*) and additive 2 (0, *AA*; 0, *AB*; 1, *BB*) scenarios, which were analyzed simultaneously with a single statistical model. The association between the genotypes of SNPs and intermediate phenotypes of MI was examined with Pearson\'s χ^2^ test. The association between genotypes of SNPs and systolic or diastolic BP, the serum concentration of creatinine, or eGFR was examined by one-way analysis of variance (ANOVA). Bonferroni\'s correction was also applied to other statistical analysis as indicated. Statistical tests were performed with JMP Genomics version 9.0 software (SAS Institute, Cary, NC, USA).

Results
=======

Characteristics of subjects
---------------------------

The characteristics of the 6,926 subjects enrolled in the MI study are shown in [Table I](#tI-ijmm-42-05-2415){ref-type="table"}. The age, the frequency of men, and the prevalence of obesity, hypertension, diabetes mellitus, dyslipidemia, CKD, and hyperuricemia, in addition to body mass index (BMI), systolic and diastolic BP, fasting plasma glucose (FPG) level, blood glycosylated hemoglobin (hemoglobin A~1c~) content, and the serum concentrations of triglycerides, creatinine, and uric acid were higher, whereas the serum concentration of high density lipoprotein (HDL)-cholesterol and eGFR were lower, in subjects with MI than in controls.

The characteristics of the 8,080 subjects enrolled in the hypertension study are shown in [Table II](#tII-ijmm-42-05-2415){ref-type="table"}. The age, the frequency of men, and the prevalence of obesity, diabetes mellitus, dyslipidemia, CKD, and hyperuricemia, in addition to the BMI, FPG level, blood hemoglobin A~1c~ content, and the serum concentrations of triglycerides, creatinine, and uric acid were higher, whereas the serum concentration of HDL-cholesterol and eGFR were lower, in subjects with hypertension than in controls.

The characteristics of the 2,556 subjects enrolled in the CKD study are shown in [Table III](#tIII-ijmm-42-05-2415){ref-type="table"}. The age, the frequency of men, and the prevalence of obesity, hypertension, diabetes mellitus, dyslipidemia, and hyperuricemia, in addition to the BMI, systolic and diastolic BP, FPG level, blood hemoglobin A~1c~ content, and the serum concentrations of triglycerides and uric acid were higher, whereas the serum concentration of HDL-cholesterol was lower, in subjects with CKD than in controls.

EWASs for MI, hypertension, and CKD
-----------------------------------

The association between allele frequencies for the 31,245, 31,276, and 31,514 SNPs that passed quality control to MI, hypertension, and CKD, respectively, were examined using Fisher\'s exact test. Following Bonferroni\'s correction, 25 and 11 SNPs were significantly (P\<1.60×10^−6^) associated with MI ([Table IV](#tIV-ijmm-42-05-2415){ref-type="table"}) or hypertension ([Table V](#tV-ijmm-42-05-2415){ref-type="table"}), respectively, and 11 SNPs were significantly (P\<1.59×10^−6^) associated with CKD ([Table VI](#tVI-ijmm-42-05-2415){ref-type="table"}).

Multivariable logistic regression analysis of the association between SNPs and MI, hypertension, or CKD
-------------------------------------------------------------------------------------------------------

The association of the 25 SNPs identified in the EWAS for MI with this condition was further examined by multivariable logistic regression analysis with adjustment for age, sex, and the prevalence of hypertension, diabetes mellitus, and dyslipidemia ([Table VII](#tVII-ijmm-42-05-2415){ref-type="table"}). All 25 SNPs were significantly \[P\<0.0005 (0.05/100) in at least one genetic model\] associated with MI. The association between the 11 SNPs identified in the EWAS for hypertension and this condition was examined by multivariable logistic regression analysis with adjustment for age and sex ([Table VIII](#tVIII-ijmm-42-05-2415){ref-type="table"}). All 11 SNPs were significantly \[P\<0.0011 (0.05/44)\] associated with hypertension. The association between the 11 SNPs identified by the EWAS for CKD and this condition was also examined by multivariable logistic regression analysis with adjustment for age, sex, and the prevalence of hypertension and diabetes mellitus ([Table IX](#tIX-ijmm-42-05-2415){ref-type="table"}). All 11 SNPs were significantly \[P\<0.0011 (0.05/44)\] associated with CKD.

Association between SNPs associated with MI and intermediate phenotypes
-----------------------------------------------------------------------

The present study examined the associations between the 25 SNPs associated with MI and intermediate phenotypes of this condition, including hypertension, diabetes mellitus, hypertriglyceridemia, hypo-HDL-cholesterolemia, hyper-low density lipoprotein (LDL)-cholesterolemia, CKD, obesity, and hyperuricemia, using Pearson\'s χ^2^ test. The SNPs rs200787930 of *PLCB2*, rs188378669 of *CXCL8*, rs61734696 of *MARCH1*, rs199921354 of *VPS33B*, rs115287176 of *TMOD4*, rs146092501 of *COL6A3*, rs146879198 of *ZNF77*, and rs192210727 of *ADGRL3* were significantly \[P\<0.0003 (0.05/200)\] associated with hypo-HDL-cholesterolemia, hyper-LDL-cholesterolemia, and CKD, with rs61734696 also being associated with hypertension. The SNPs rs671 of *ALDH2*, rs11066015 of *ACAD10*, and rs11066280 and rs2074356 of *HECTD4* were significantly associated with hypo-HDL-cholesterolemia, hyper-LDL-cholesterolemia, and hyperuricemia. The SNPs rs3782886 of *BRAP* and rs12229654 at 12q24.1 were significantly associated with hypo-HDL-cholesterolemia and hyperuricemia. The SNP rs11823828 of *OR52E4* was significantly associated with diabetes mellitus, rs12231744 of *NAA25* with hypo-HDL-cholesterolemia, rs7969300 of *ATXN2* with hyper-triglyceridemia, and rs10774610 and rs10849915 of *CCDC63* with hyperuricemia ([Table X](#tX-ijmm-42-05-2415){ref-type="table"}).

Association between SNPs associated with hypertension and systolic or diastolic BP
----------------------------------------------------------------------------------

The present study examined the associations between genotypes for the 11 SNPs associated with hypertension and systolic or diastolic BP by one-way ANOVA ([Table XI](#tXI-ijmm-42-05-2415){ref-type="table"}). All 11 SNPs were significantly \[P\<0.0023 (0.05/22)\] associated with systolic BP, whereas only rs2071593 of *NFKBIL1* was associated with diastolic BP.

Association between SNPs associated with CKD and the serum concentration of creatinine or eGFR
----------------------------------------------------------------------------------------------

The present study examined the associations between the 11 SNPs associated with CKD and the serum concentration of creatinine or eGFR by one-way ANOVA ([Table XII](#tXII-ijmm-42-05-2415){ref-type="table"}). All 11 SNPs were significantly \[P\<0.0023 (0.05/22)\] associated with eGFR, however, none were associated with the serum concentration of creatinine.

Linkage disequilibrium analyses
-------------------------------

The linkage disequilibrium (LD) among SNPs associated with MI, hypertension, or CKD was examined. For the MI study, rs192210727 of *ADGRL3*, rs188378669 of *CXCL8*, and rs61734696 of *MARCH1* were in LD \[square of the correlation coefficient (*r*^2^), 0.907-0.972\]. Two SNPs (rs2596548, rs2523644) at chromosome 6p21.3 were also in LD (*r*^2^=0.624). LD plots of the 13 SNPs located at chromosome 12q24.11 to 12q24.13 are shown in [Fig. 1](#f1-ijmm-42-05-2415){ref-type="fig"}. There was significant LD between rs74416240 of *TCHP* and rs925368 of *GIT2* (*r*^2^=0.937); between rs10849915 and rs10774610 of *CCDC63* (*r*^2^=0.992); and among rs3782886 of *BRAP*, rs11066015 of *ACAD10*, rs671 of *ALDH2*, and rs2074356 and rs11066280 of *HECTD4* (*r*^2^=0.814-0.994). A significant LD (*r*^2^=0.994) was also apparent between rs200787930 of *PLCB2* and rs199921354 of *VPS33B*.

For the hypertension study, there was significant LD between rs139537100 of *MOB3C* and rs115287176 of *TMOD4* (*r*^2^=0.984); between rs188378669 of *CXCL8* and rs61734696 of *MARCH1* (*r*^2^=0.972); among rs2071593 of *NFKBIL1*, rs769177 at 6p21.3, and rs2515920 of *NCR3* (*r*^2^=0.883-0.980); and between rs200787930 of *PLCB2* and rs199921354 of *VPS33B* (*r*^2^=0.994).

For the CKD study, complete LD (*r*^2^=1.000) was apparent between rs139537100 of *MOB3C* and rs115287176 of *TMOD4*, and between rs200787930 of *PLCB2* and rs199921354 of *VPS33B*. Significant LD (*r*^2^=0.905-0.952) was also observed among rs192210727 of *ADGRL3*, rs188378669 of *CXCL8*, and rs61734696 of *MARCH1*.

Associations between the genes, chromosomal loci and SNPs identified in the present study and the phenotypes examined in previous GWASs
---------------------------------------------------------------------------------------------------------------------------------------

The present study examined the association of the genes, chromosomal loci and SNPs identified in the present study with the phenotypes previously investigated by GWASs available in the Genome-Wide Repository of Associations Between SNPs and Phenotypes Search database (<https://grasp.nhlbi.nih.gov/Search.aspx>) developed by the Information Technology and Applications Center at the National Center for Biotechnology Information (National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA) ([@b60-ijmm-42-05-2415],[@b61-ijmm-42-05-2415]).

For the MI study, chromosomal region 6p21.3, *ATXN2*, *BRAP*, *ACAD10*, *ALDH2*, *NAA25*, and *HECTD4* were previously shown to be associated with MI or CAD ([Table XIII](#tXIII-ijmm-42-05-2415){ref-type="table"}). The remaining 15 genes or loci identified in the present study have not been previously found to be associated with MI or CAD, although *GOSR2* was previously found to be associated with systolic BP. For the hypertension study, none of the genes, chromosomal loci, or SNPs identified were found to be associated with systolic or diastolic BP or with hypertension in previous GWASs, although 6p21.3 was previously shown to be associated with CAD ([Table XIV](#tXIV-ijmm-42-05-2415){ref-type="table"}). For the CKD study, none of the genes or SNPs identified were shown to be associated with renal function-related traits or CKD in previous GWASs ([Table XV](#tXV-ijmm-42-05-2415){ref-type="table"}).

Gene Ontology (GO) analysis of genes identified in the present study
--------------------------------------------------------------------

The potential biological functions of the 18 genes (*MOB3C*, *TMOD4*, *COL6A3*, *ADGRL3*, *CXCL8*, *MARCH1*, *OR52E4*, *TCHP*, *GIT2*, *CCDC63*, *OAS3*, *PLCB2*, *VPS33B*, *ZNF77*, *COL6A5*, *NFKBIL1*, *NCR3*, *MUC17*) identified in the present study were examined with the use of the QuickGO database of Gene Ontology and GO Annotations (<https://www.ebi.ac.uk/QuickGO>; European Bioinformatics Institute, European Molecular Biology Laboratory, Hinxton, UK) ([@b62-ijmm-42-05-2415],[@b63-ijmm-42-05-2415]). The GO analysis predicted various biological functions for the 18 genes, including those associated with muscle contraction (*TMOD4*), cell adhesion (*COL6A3*, *COL6A5*), G protein-coupled receptor signaling (*ADGRL3*, *OR52E4*, *PLCB2*), the inflammatory response (*CXCL8*), the immune response (*MARCH1*, *OAS3 NCR3*), apoptosis (*TCHP*), GTPase activity (*GIT2*), protein transport (*VPS33B*), NF-κB signaling (*NFKBIL1*), and lectin receptor signaling (*MUC17*) ([Table XVI](#tXVI-ijmm-42-05-2415){ref-type="table"}).

Network analysis of genes identified in the present study
---------------------------------------------------------

Network analysis of the 18 genes identified in the present study was performed to predict functional gene-gene interactions with the use of the GeneMANIA Cytoscape plugin (<http://apps.cytoscape.org/apps/genemania>; Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, Toronto, ON, Canada) ([@b64-ijmm-42-05-2415]-[@b66-ijmm-42-05-2415]) and Cytoscape v3.4.0 software (<http://www.cytoscape.org>; The Cytoscape Consortium, San Diego, CA, USA) ([@b67-ijmm-42-05-2415]). Three sets of 50 genes were selected from the DisGeNET database (<http://www.disgenet.org/web/DisGeNET>; Integrative Biomedical Informatics Group, Research Programme on Biomedical Informatics, Barcelona Biomedical Research Park, Barcelona, Spain) ([@b68-ijmm-42-05-2415],[@b69-ijmm-42-05-2415]) according to the rank order (high to low) of scores for association with MI, hypertension, or CKD ([Fig. 2](#f2-ijmm-42-05-2415){ref-type="fig"}). The network analysis revealed that the 13 ([Fig. 2A](#f2-ijmm-42-05-2415){ref-type="fig"}), 10 ([Fig. 2B](#f2-ijmm-42-05-2415){ref-type="fig"}), and 11 ([Fig. 2C](#f2-ijmm-42-05-2415){ref-type="fig"}) genes found to be associated with MI, hypertension, and CKD, respectively, in the present study have potential direct or indirect interactions with the corresponding sets of 50 genes previously shown to be associated with these conditions.

Discussion
==========

As the prevalence of cardiovascular and renal diseases is increasing and is therefore a key public health concern ([@b1-ijmm-42-05-2415],[@b20-ijmm-42-05-2415],[@b31-ijmm-42-05-2415],[@b32-ijmm-42-05-2415]), the identification of genetic variants that confer susceptibility to MI, hypertension, and CKD is important to prevent these conditions. In the present study, EWASs for MI, hypertension, and CKD were performed in subjects with early-onset forms of these conditions, with genetic factors likely to be more important in these individuals compared with those with late-onset forms.

In the MI study, it was found that 25 SNPs of 20 genes and two chromosomal loci were significantly associated with early-onset MI. Among these genes and loci, 6p21.3 ([@b16-ijmm-42-05-2415]), *ATXN2* ([@b9-ijmm-42-05-2415]), *BRAP* ([@b16-ijmm-42-05-2415]), *ACAD10* ([@b9-ijmm-42-05-2415]), *ALDH2* ([@b9-ijmm-42-05-2415]), *NAA25* ([@b9-ijmm-42-05-2415]), and *HECTD4* ([@b9-ijmm-42-05-2415]) have previously been shown to be associated with MI or CAD. Therefore, 16 SNPs of 14 genes and one locus were newly identified. However, significant LD was detected among three SNPs in *ADGRL3*, *CXCL8*, and *MARCH1*; between two SNPs in *TCHP* and *GIT2*; between two SNPs in *CCDC63*; and between two SNPs in *PLCB2* and *VPS33B*. Therefore, 11 novel loci (*TMOD4*, *COL6A3*, *ADGRL3-CXCL8-MARCH1*, *OR52E4*, *TCHP-GIT2*, *CCDC63*, 12q24.1, *OAS3*, *PLCB2-VPS33B*, *GOSR2*, *ZNF77*) were identified that confer susceptibility to MI.

In the hypertension study, 11 SNPs of 10 genes and one chromosomal locus were significantly associated with early-onset hypertension. None of these genes or loci have been found to be associated with systolic or diastolic BP or with hypertension in previous GWASs. However, there was significant LD between two SNPs in *MOB3C* and *TMOD4*; between two SNPs in *CXCL8* and *MARCH1*; among three SNPs of *NFKBIL1*, 6p21.3, and *NCR3*; and between two SNPs in *PLCB2* and *VPS33B*. Therefore six novel loci (*MOB3C-TMOD4*, *COL6A3*, *COL6A5*, *CXCL8-MARCH1*, *NFKBIL1-*6p21.3*-NCR3*, *PLCB2-VPS33B*) were identified that confer susceptibility to hypertension.

In the CKD study, 11 SNPs in 11 genes were significantly associated with early-onset CKD. None of these genes have been shown to be associated with renal function-related traits or CKD in previous GWASs. However, there was significant LD between two SNPs in *MOB3C* and *TMOD4*; between two SNPs in *PLCB2* and *VPS33B*; and among three SNPs in *ADGRL3*, *CXCL8*, and *MARCH1*. Therefore, seven new loci (*MOB3C-TMOD4*, *COL6A3*, *COL6A5*, *ADGRL3-CXCL8-MARCH1*, *MUC17*, *PLCB2-VPS33B*, *ZNF77*) were identified that confer susceptibility to CKD.

Furthermore, rs115287176 of *TMOD4*, rs146092501 of *COL6A3*, rs188378669 of *CXCL8*, rs61734696 of *MARCH1*, rs200787930 of *PLCB2*, and rs199921354 of *VSP33B* were significantly associated with all three diseases (MI, hypertension, and CKD); rs192210727 of *ADGRL3* and rs146879198 of *ZNF77* were associated with both MI and CKD; and rs200982668 of *COL6A5* and rs139537100 of *MOB3C* were associated with both hypertension and CKD. In addition, *GOSR2*, which was associated with MI, has previously been shown to be associated with systolic BP ([@b23-ijmm-42-05-2415]); and 6p21.3, which was associated with hypertension, has previously been shown to be associated with CAD ([@b16-ijmm-42-05-2415]). Therefore, 13 loci (*MOB3C-TMOD4*, *COL6A3*, *ADGRL3-CXCL8-MARCH1*, *OR52E4*, *TCHP- GIT2*, *CCDC63*, 12q24.1, *OAS3*, *PLCB2-VPS33B*, *ZNF77*, *COL6A5*, *NFKBIL1-NCR3*, *MUC17*) were newly identified that confer susceptibility to MI, hypertension, or CKD. Genes, chromosomal loci, and SNPs identified in the present study, in particular, those significantly associated with two or three diseases, may prove to be informative for clinical practice.

In the MI study, associations of *CXCL8* to plasma total cholesterol ([@b70-ijmm-42-05-2415]), of *MARCH1* to serum adiponectin concentration ([@b71-ijmm-42-05-2415]), of 12q24.1 and *OAS3* to plasma HDL-cholesterol ([@b72-ijmm-42-05-2415]), of *PLCB2* to plasma triglycerides ([@b70-ijmm-42-05-2415]), of *VPS33B* to type 2 diabetes mellitus ([@b73-ijmm-42-05-2415]), and of *GOSR2* to systolic BP ([@b23-ijmm-42-05-2415]) have been shown in previous GWASs. In the present study, eight loci (*TMOD4*, *COL6A3*, *ADGRL3-CXCL8-MARCH1*, *OR52E4*, *CCDC63*, 12q24.1, *PLCB2-VPS33B*, *ZNF77*) newly associated with MI were significantly associated with one or more intermediate phenotypes; in particular, five loci (*TMOD4*, *COL6A3*, *ADGRL3-CXCL8-MARCH1*, *PLCB2-VPS33B*, *ZNF77)* associated with two or three diseases were associated with three or four intermediate phenotypes. As these intermediate phenotypes are important risk factors for MI, the association between these loci and MI may be attributable, at least in part, to their effects on intermediate phenotypes. By contrast, three loci (*TCHP-GIT2*, *OAS3*, and *GOSR2*) associated with MI were not associated with intermediate phenotypes. The molecular mechanisms underlying the association between these loci and MI remain to be elucidated.

In the hypertension study, although the six loci (*MOB3C-TMOD4*, *COL6A3*, *COL6A5*, *CXCL8-MARCH1*, *NFKBIL1-*6p21.3*-NCR3*, *PLCB2-VPS33B*) identified in the present study were all significantly associated with systolic BP, they have not been shown to be associated with BP or hypertension by previous GWASs. The associations of *NFKBIL1* and *NCR3* to plasma total cholesterol ([@b74-ijmm-42-05-2415]), of 6p21.3 to plasma total cholesterol and triglycerides ([@b74-ijmm-42-05-2415]), and of *CXCL8* ([@b70-ijmm-42-05-2415]), *MARCH1* ([@b71-ijmm-42-05-2415]), *PLCB2* ([@b70-ijmm-42-05-2415]), and *VPS33B* ([@b73-ijmm-42-05-2415]) to lipid or glucose metabolism have been shown in previous GWASs. The effects of these loci on lipid or glucose metabolism may influence BP or hypertension, although the functional relevance of these loci to the pathogenesis of hypertension remains to be fully elucidated.

In the CKD study, although the seven loci (*MOB3C-TMOD4*, *COL6A3*, *COL6A5*, *ADGRL3-CXCL8-MARCH1*, *MUC17*, *PLCB2-VPS33B*, *ZNF77*) identified in the present study were all significantly associated with eGFR, they have not been shown to be associated with renal function-related traits or CKD in previous GWASs. The associations of *CXCL8* ([@b70-ijmm-42-05-2415]), *MARCH1* ([@b71-ijmm-42-05-2415]), *PLCB2* ([@b70-ijmm-42-05-2415]), and *VPS33B* ([@b73-ijmm-42-05-2415]) to lipid or glucose metabolism have been demonstrated in previous GWASs. The effects of these loci on lipid or glucose metabolism may contribute, at least in part, to renal function or the development of CKD, although the molecular mechanisms underlying the association between these loci and CKD remain to be elucidated.

Previous GWASs have identified potential biological pathways underlying the associations between genetic loci and CAD ([@b75-ijmm-42-05-2415],[@b76-ijmm-42-05-2415]). Network analysis of functional gene-gene interactions may be informative with regard to the clarification of biological processes underlying CAD and to the identification of therapeutic targets for this condition ([@b77-ijmm-42-05-2415]). Therefore the present study performed GO and network analyses to predict biological processes associated with the identified genes, and the interactions between these genes and those previously shown to be associated with MI, hypertension, or CKD.

GO analysis of the 13 genes associated with MI suggested that the functions of *TMOD4* (actin filament organization); *COL6A3* (cell adhesion and extracellular matrix organization); *ADGRL3*, *OR52E4*, and *PLCB2* (G protein-coupled receptor signaling); *CXCL8* (angiogenesis and inflammatory response); *MARCH1* and *OAS3* (immune response); *TCHP* (apoptotic process); *GIT2* (regulation of GTPase activity); and *VPS33B* (vesicle-mediated transport and platelet α-granule organization) may be associated with the pathogenesis of MI. For the 10 genes associated with hypertension, the functions of *TMOD4*, *COL6A3*, *COL6A5* (cell adhesion), *CXCL8*, *MARCH1*, *NFKBIL1* (NF-κB signaling), *NCR3* (immune response), *PLCB2*, and *VPS33B* may be associated with the pathogenesis of hypertension. Among the 11 genes associated with CKD, the functions of *COL6A3*, *COL6A5*, *ADGRL3*, *CXCL8*, *MARCH1*, *MUC17* (cellular homeostasis), *PLCB2*, and *VPS33B* may be associated with the pathogenesis of CKD. Network analysis showed that the 13, 10, and 11 genes found to be associated with MI, hypertension, and CKD, respectively, in the present study had direct or indirect interactions with the corresponding sets of 50 genes selected from the DisGeNET database ([@b68-ijmm-42-05-2415],[@b69-ijmm-42-05-2415]). However, the underlying molecular mechanisms of these interactions remain to be elucidated.

In our previous studies, it was shown that nine, nine, and four SNPs were associated with MI (P\<0.01), hypertension (P\<0.01), and CKD (P\<0.05), respectively, as determined by multivariable logistic regression analysis with adjustment for covariates following an initial EWAS screening of allele frequencies among subjects with early-onset and late-onset forms of these conditions ([@b50-ijmm-42-05-2415]-[@b52-ijmm-42-05-2415]). The associations between five of the nine SNPs \[rs202103723 (P=0.0107), rs188212047 (P=0.0039), rs1265110 (P=0.0004), rs9258102 (P=0.0373), rs439121 (P=0.0063)\] and MI were replicated (P\<0.05) in the present study. The associations between six of the nine SNPs \[rs150854849 (P=0.0123), rs2867125 (P=0.0111), rs202069030 (P=6.40×10^−10^), rs139012426 (P=5.50×10^−6^), rs12229654 (P=0.0003), rs201633733 (P=0.0356)\] and hypertension were replicated (P\<0.05) in the present study. By contrast, none of the associations between the four SNPs and CKD were replicated in the present study, indicative of the importance of age in the development of CKD. These results suggested that genetic variants associated with MI, hypertension, and CKD differ, in part, between individuals with early-onset and late-onset disease.

There were several limitations to the present study: i) As that the results were not replicated, their validation is necessary in independent study populations or in other ethnicities; ii) it is possible that SNPs identified in the present study are in LD with other genetic variants in the same gene or in other nearby genes that are actually responsible for the development of MI, hypertension, or CKD; iii) the functional relevance of identified SNPs to the pathogenesis of MI, hypertension, and CKD remains to be elucidated. Due to the lack of experiments for functional analyses, the association of the SNPs identified in the present study with MI, hypertension, and CKD requires careful interpretation.

In conclusion, the present study identified 13 loci (*MOB3C-TMOD4*, *COL6A3*, *ADGRL3-CXCL8-MARCH1*, *OR52E4*, *TCHP- GIT2*, *CCDC63*, 12q24.1, *OAS3*, *PLCB2-VPS33B*, *ZNF77*, *COL6A5*, *NFKBIL1-NCR3*, *MUC17*) that confer susceptibility to MI, hypertension, or CKD. Determination of the genotypes for the SNPs at these loci may provide informative for assessment of the genetic risk for MI, hypertension, and CKD.
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###### 

\(A\) Network analysis of the 13 genes (*TMOD4, COL6A3, ADGRL3, CXCL8, MARCH1, OR52E4, TCHP, GIT2, CCDC63, OAS3, PLCB2, VPS33B, ZNF77*) associated with MI in the present study (red circles) was performed to predict functional gene-gene interactions with the use of the GeneMANIA Cytoscape plugin (<http://apps.cytoscape.org/apps/genemania>) and Cytoscape v3.4.0 software (<http://www.cytoscape.org>). A total of 50 genes (green circles) selected from the DisGeNET database (<http://www.disgenet.org/web/DisGeNET>) according to the rank order (high to low) of scores for association with MI were applied to the analysis. Interactions between red circles or between red and green circles are indicated by bold lines. Molecules represented by gray circles are putative mediators of interactions between genes. (B) Network analysis of the 10 genes (*MOB3C, TMOD4, COL6A3, COL6A5, CXCL8, MARCH1, NFKBIL1, NCR3, PLCB2, VPS33B*) associated with hypertension in the present study (red circles) was performed in the same manner; 50 genes (green circles) selected from the DisGeNET database according to the rank order of scores for association with hypertension were applied to the analysis. MI, myocardial infarction. (C) Network analysis of the 11 genes (*MOB3C, TMOD4, COL6A3, COL6A5, ADGRL3, CXCL8, MARCH1, MUC17, PLCB2, VPS33B, ZNF77*) associated with CKD in the present study (red circles) was performed in the same manner; 50 genes (green circles) selected from the DisGeNET database according to the rank order of scores for association with CKD were applied to the analysis. CKD, chronic kidney disease.
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###### 

Characteristics of subjects with MI and control individuals.

  Characteristic                    Control     Myocardial infarction   P-value
  --------------------------------- ----------- ----------------------- ----------
  Subjects (n)                      5,774       1,152                   
  Age (years)                       50.6±10.2   55.6±7.4                \<0.0001
  Sex (men/women, %)                52.1/47.9   85.4/14.6               \<0.0001
  Smoking (%)                       42.5        46.7                    0.0105
  Obesity (%)                       31.0        42.7                    \<0.0001
  Body mass index (kg/m^2^)         23.2±3.5    24.6±3.5                \<0.0001
  Hypertension (%)                  31.7        68.9                    \<0.0001
  Systolic BP (mmHg)                121±18      139±26                  \<0.0001
  Diastolic BP (mmHg)               75±13       78±16                   \<0.0001
  Diabetes mellitus (%)             12.7        61.3                    \<0.0001
  Fasting plasma glucose (mmol/l)   5.66±1.78   7.66±3.39               \<0.0001
  Blood hemoglobin A1c (%)          5.72±0.96   6.88±1.70               \<0.0001
  Dyslipidemia (%)                  56.9        84.9                    \<0.0001
  Serum triglycerides (mmol/l)      1.32±0.98   1.77±1.25               \<0.0001
  Serum HDL-cholesterol (mmol/l)    1.65±0.45   1.17±0.34               \<0.0001
  Serum LDL-cholesterol (mmol/l)    3.18±0.83   3.15±0.98               0.8593
  Chronic kidney disease (%)        10.3        29.1                    \<0.0001
  Serum creatinine (µmol/l)         69.8±61.0   91.9±98.1               \<0.0001
  eGFR (ml min^−1^ 1.73 m^−2^)      78.7±17.1   71.2±27.8               \<0.0001
  Hyperuricemia (%)                 15.2        25.6                    \<0.0001
  Serum uric acid (µmol/l)          321±89      356±105                 \<0.0001

Quantitative data are presented as the mean ± standard deviation and were compared between subjects with MI and controls using the unpaired t-test. Categorical data were compared between the two groups with Pearson\'s χ^2^ test. Based on Bonferroni\'s correction, P\<0.0025 (0.05/20) was considered statistically significant. Obesity was defined as a body mass index of ≥25 kg/m^2^; hypertension as a systolic BP of ≥140 mmHg, diastolic BP of ≥90 mmHg, or the taking of anti-hypertensive medication; diabetes mellitus as a fasting plasma glucose level of ≥6.93 mmol/l, blood hemoglobin A1c content of ≥6.5%, or the taking of antidiabetic medication; dyslipidemia as a serum triglyceride concentration of ≥1.65 mmol/l, serum HDL-cholesterol \<1.04 mmol/l, serum LDL-cholesterol ≥3.64 mmol/l, or the taking of anti-dyslipidemic medication; chronic kidney disease as an eGFR of \<60 ml min^−1^ 1.73 m^−2^; and hyperuricemia as a serum uric acid concentration of \>416 µmol/l or the taking of uric acid-lowering medication. MI, myocardial infarction; BP, blood pressure; HDL, high density lipoprotein; LDL, low density lipoprotein; eGFR, estimated glomerular filtration rate.

###### 

Characteristics of subjects with hypertension and control individuals.

  Characteristic                    Control     Hypertension   P-value
  --------------------------------- ----------- -------------- ----------
  Subjects (n)                      4636        3444           
  Age (years)                       49.2±10.3   55.8±7.6       \<0.0001
  Sex (men/women, %)                52.0/48.0   67.8/32.2      \<0.0001
  Smoking (%)                       41.7        42.9           0.2829
  Obesity (%)                       24.3        44.4           \<0.0001
  Body mass index (kg/m^2^)         22.6±3.3    24.5±3.7       \<0.0001
  Systolic BP (mmHg)                114±12      144±24         \<0.0001
  Diastolic BP (mmHg)               70±10       85±14          \<0.0001
  Diabetes mellitus (%)             11.1        39.5           \<0.0001
  Fasting plasma glucose (mmol/l)   5.61±1.78   6.72±2.83      \<0.0001
  Blood hemoglobin A1c (%)          5.71±0.96   6.30±1.48      \<0.0001
  Dyslipidemia (%)                  51.3        75.5           \<0.0001
  Serum triglycerides (mmol/l)      1.25±0.98   1.69±1.19      \<0.0001
  Serum HDL-cholesterol (mmol/l)    1.63±0.46   1.41±0.45      \<0.0001
  Serum LDL-cholesterol (mmol/l)    3.15±0.85   3.15±0.88      0.9206
  Chronic kidney disease (%)        8.1         24.0           \<0.0001
  Serum creatinine (µmol/l)         65.4±23.9   89.3±117.6     \<0.0001
  eGFR (ml min^−1^ 1.73 m^−2^)      80.4±18.8   72.5±21.3      \<0.0001
  Hyperuricemia (%)                 11.3        25.2           \<0.0001
  Serum uric acid (µmol/l)          311±86      349±99         \<0.0001

Quantitative data are presented as the mean ± standard deviation and were compared between subjects with hypertension and controls with the unpaired t-test. Categorical data were compared between the two groups with Pearson\'s χ^2^ test. Based on Bonferroni\'s correction, P\<0.0026 (0.05/19) was considered statistically significant. Obesity was defined as a body mass index of ≥25 kg/m^2^; hypertension as a systolic BP of ≥140 mmHg, diastolic BP of ≥90 mmHg, or the taking of antihypertensive medication; diabetes mellitus as a fasting plasma glucose level of ≥6.93 mmol/l, blood hemoglobin A1c content of ≥6.5%, or the taking of antidiabetic medication; dyslipidemia as a serum triglyceride concentration of ≥1.65 mmol/l, serum HDL-cholesterol \<1.04 mmol/l, serum LDL-cholesterol ≥3.64 mmol/l, or the taking of anti-dyslipidemic medication; chronic kidney disease as an eGFR of \<60 ml min^−1^ 1.73 m^−2^; and hyperuricemia as a serum uric acid concentration of \>416 µmol/l or the taking of uric acid-lowering medication. BP, blood pressure; HDL, high density lipoprotein; LDL, low density lipoprotein; eGFR, estimated glomerular filtration rate.

###### 

Characteristics of subjects with CKD and control individuals.

  Characteristic                    Control      CKD           P-value
  --------------------------------- ------------ ------------- ----------
  Subjects (n)                      1,505        1,051         
  Age (years)                       48.5±10.3    57.7±6.5      \<0.0001
  Sex (men/women, %)                53.8/46.2    68.9/31.1     \<0.0001
  Smoking (%)                       43.2         37.3          0.0028
  Obesity (%)                       29.1         38.9          \<0.0001
  Body mass index (kg/m^2^)         23.1±3.8     24.1±3.5      \<0.0001
  Hypertension (%)                  36.5         71.4          \<0.0001
  Systolic BP (mmHg)                126±23       141±29        \<0.0001
  Diastolic BP (mmHg)               76±14        80±16         \<0.0001
  Diabetes mellitus (%)             24.8         45.2          \<0.0001
  Fasting plasma glucose (mmol/l)   6.27±2.72    6.88±3.16     \<0.0001
  Blood hemoglobin A1c (%)          6.08±1.51    6.42±1.51     \<0.0001
  Dyslipidemia (%)                  56.4         75.3          \<0.0001
  Serum triglycerides (mmol/l)      1.35±1.21    1.69±1.07     \<0.0001
  Serum HDL-cholesterol (mmol/l)    1.56±0.47    1.38±0.48     \<0.0001
  Serum LDL-cholesterol (mmol/l)    3.08±0.85    3.13±0.93     0.0738
  Serum creatinine (µmol/l)         51.7±9.3     150.3±198.0   \<0.0001
  eGFR (ml min^−1^ 1.73 m^−2^)      103.0±19.1   46.9±14.6     \<0.0001
  Hyperuricemia (%)                 8.5          40.6          \<0.0001
  Serum uric acid (µmol/l)          297±80       381±106       \<0.0001

Quantitative data are presented as the mean ± standard deviation and were compared between subjects with CKD and controls with the unpaired t-test. Categorical data were compared between the two groups with Pearson\'s χ^2^ test. Based on Bonferroni\'s correction, P\<0.0026 (0.05/19) was considered statistically significant. Obesity was defined as a body mass index of ≥25 kg/m^2^; hypertension as a systolic BP of ≥140 mmHg, diastolic BP of ≥90 mmHg, or the taking of antihypertensive medication; diabetes mellitus as a fasting plasma glucose level of ≥6.93 mmol/l, blood hemoglobin A1c content of ≥6.5%, or the taking of antidiabetic medication; dyslipidemia as a serum triglyceride concentration of ≥1.65 mmol/l, serum HDL-cholesterol \<1.04 mmol/l, serum LDL-cholesterol ≥3.64 mmol/l, or the taking of anti-dyslipidemic medication; chronic kidney disease as an eGFR of \<60 ml min^−1^ 1.73 m^−2^; and hyperuricemia as a serum uric acid concentration of \>416 µmol/l or the taking of uric acid-lowering medication. CKD, chronic kidney disease; BP, blood pressure; HDL, high density lipoprotein; LDL, low density lipoprotein; eGFR, estimated glomerular filtration rate.

###### 

25 SNPs significantly (P\<1.60×10^−6^) associated with myocardial infarction in the exome-wide association study.

  Gene       SNP           Nucleotide substitution[a](#tfn5-ijmm-42-05-2415){ref-type="table-fn"}   Amino acid substitution   Chromosome   Position    MAF (%)   Allele OR   P-value (allele frequency)
  ---------- ------------- ------------------------------------------------------------------------ ------------------------- ------------ ----------- --------- ----------- ----------------------------
  *PLCB2*    rs200787930   C/T                                                                      E1106K                    15           40289298    1.2       0.01        8.81×10^−26^
  *CXCL8*    rs188378669   G/T                                                                      E31\*                     4            73741568    1.2       0.01        1.33×10^−25^
  *MARCH1*   rs61734696    G/T                                                                      Q137K                     4            164197303   1.2       0.01        1.50×10^−25^
  *VPS33B*   rs199921354   C/T                                                                      R80Q                      15           91013841    1.2       0.01        2.07×10^−25^
  *TMOD4*    rs115287176   G/A                                                                      R277W                     1            151170961   1.2       0.01        9.03×10^−25^
  *COL6A3*   rs146092501   C/T                                                                      E1386K                    2            237371861   1.2       0.02        1.27×10^−24^
  *ZNF77*    rs146879198   G/A                                                                      R340\*                    19           2934109     1.2       0.02        1.27×10^−24^
  *ADGRL3*   rs192210727   G/T                                                                      R580I                     4            61909615    1.3       0.07        1.12×10^−20^
  *ALDH2*    rs671         G/A                                                                      E504K                     12           111803962   27.6      1.54        2.67×10^−19^
  *ACAD10*   rs11066015    G/A                                                                                                12           111730205   27.5      0.65        3.35×10^−19^
  *BRAP*     rs3782886     A/G                                                                                                12           111672685   29.3      1.49        5.52×10^−17^
  *HECTD4*   rs11066280    T/A                                                                                                12           112379979   29.0      1.49        6.48×10^−17^
  *HECTD4*   rs2074356     C/T                                                                                                12           112207597   25.4      1.48        4.24×10^−15^
  *OR52E4*   rs11823828    T/G                                                                      F227L                     11           5884973     36.6      1.43        1.86×10^−12^
             rs12229654    T/G                                                                                                12           110976657   22.5      1.39        1.45×10^−10^
  *NAA25*    rs12231744    C/T                                                                      R876K                     12           112039251   35.1      0.74        1.07×10^−9^
  *ATXN2*    rs7969300     T/C                                                                      N248S                     12           111555908   38.8      0.76        8.46×10^−9^
  *GOSR2*    rs1052586     T/C                                                                                                17           46941097    48.7      0.78        1.80×10^−7^
  *TCHP*     rs74416240    G/A                                                                                                12           109904793   13.3      1.37        2.47×10^−7^
  *GIT2*     rs925368      A/G                                                                      N389S                     12           109953174   12.5      1.37        4.41×10^−7^
             rs2523644     A/G                                                                                                6            31374707    8.1       1.49        4.75×10^−7^
  *OAS3*     rs2072134     C/T                                                                                                12           112971371   17.6      1.33        5.28×10^−7^
  *CCDC63*   rs10774610    T/C                                                                                                12           110902439   23.7      1.30        5.42×10^−7^
             rs2596548     G/T                                                                                                6            31362769    5.4       1.60        6.01×10^−7^
  *CCDC63*   rs10849915    T/C                                                                                                12           110895818   23.6      1.28        7.71×10^−7^

Allele frequencies were analyzed using Fisher\'s exact test.

Major allele/minor allele. SNP, single nucleotide polymorphism; MAF, minor allele frequency; OR, odds ratio.

###### 

11 SNPs significantly (P\<1.60×10^−6^) associated with hypertension in the exome-wide association study.

  Gene        SNP           Nucleotide substitution[a](#tfn7-ijmm-42-05-2415){ref-type="table-fn"}   Amino acid substitution   Chromosome   Position    MAF (%)   Allele OR (allele frequency)   P-value
  ----------- ------------- ------------------------------------------------------------------------ ------------------------- ------------ ----------- --------- ------------------------------ -------------
  *MARCH1*    rs61734696    G/T                                                                      Q137K                     4            164197303   1.2       0.54                           1.30×10^−7^
  *PLCB2*     rs200787930   C/T                                                                      E1106K                    15           40289298    1.2       0.55                           3.33×10^−7^
  *COL6A3*    rs146092501   C/T                                                                      E1386K                    2            237371861   1.2       0.55                           3.50×10^−7^
  *COL6A5*    rs200982668   G/A                                                                      E2501K                    3            130470894   1.3       0.56                           3.52×10^−7^
  *MOB3C*     rs139537100   C/T                                                                      R24Q                      1            46615006    1.2       0.56                           4.76×10^−7^
  *VPS33B*    rs199921354   C/T                                                                      R80Q                      15           91013841    1.2       0.55                           4.84×10^−7^
  *NCR3*      rs2515920     T/A                                                                                                6            31594838    17.3      0.81                           5.02×10^−7^
  *TMOD4*     rs115287176   G/A                                                                      R277W                     1            151170961   1.2       0.55                           5.49×10^−7^
  *CXCL8*     rs188378669   G/T                                                                      E31\*                     4            73741568    1.2       0.56                           6.93×10^−7^
              rs769177      G/A                                                                                                6            31579834    17.2      0.81                           1.35×10^−6^
  *NFKBIL1*   rs2071593     C/T                                                                                                6            31545022    18.8      0.82                           1.59×10^−6^

Allele frequencies were analyzed using Fisher\'s exact test.

Major allele/minor allele. SNP, single nucleotide polymorphism; MAF, minor allele frequency; OR, odds ratio.

###### 

11 SNPs significantly (P\<1.59×10^−6^) associated with chronic kidney disease in the exome-wide association study.

  Gene       SNP           Nucleotide substitution[a](#tfn9-ijmm-42-05-2415){ref-type="table-fn"}   Amino acid substitution   Chromosome   Position    MAF (%)   Allele OR   P-value (allele frequency)
  ---------- ------------- ------------------------------------------------------------------------ ------------------------- ------------ ----------- --------- ----------- ----------------------------
  *COL6A5*   rs200982668   G/A                                                                      E2501K                    3            130470894   1.3       0.21        5.08×10^−9^
  *MARCH1*   rs61734696    G/T                                                                      Q137K                     4            164197303   1.2       0.22        1.97×10^−8^
  *MUC17*    rs78010183    A/T                                                                      T1305S                    7            101035329   1.8       0.29        2.04×10^−8^
  *MOB3C*    rs139537100   C/T                                                                      R24Q                      1            46615006    1.2       0.23        4.91×10^−8^
  *PLCB2*    rs200787930   C/T                                                                      E1106K                    15           40289298    1.2       0.23        4.94×10^−8^
  *CXCL8*    rs188378669   G/T                                                                      E31\*                     4            73741568    1.2       0.23        7.83×10^−8^
  *VPS33B*   rs199921354   C/T                                                                      R80Q                      15           91013841    1.2       0.23        7.86×10^−8^
  *TMOD4*    rs115287176   G/A                                                                      R277W                     1            151170961   1.2       0.23        1.25×10^−7^
  *ADGRL3*   rs192210727   G/T                                                                      R580I                     4            61909615    1.3       0.25        1.88×10^−7^
  *ZNF77*    rs146879198   G/A                                                                      R340\*                    19           2934109     1.2       0.24        2.95×10^−7^
  *COL6A3*   rs146092501   C/T                                                                      E1386K                    2            237371861   1.2       0.24        2.99×10^−7^

Allele frequencies were analyzed using Fisher\'s exact test.

Major allele/minor allele. SNP, single nucleotide polymorphism; MAF, minor allele frequency; OR, odds ratio.

###### 

Association between SNPs and myocardial infarction as determined by multivariable logistic regression analysis.

  Gene       SNP           Dominant   Recessive   Additive 1   Additive 2                                                                                 
  ---------- ------------- ---------- ----------- ------------ ------------ ---------- ------ ----------- ---------- ------ ----------- ---------- ------ -----------
  *PLCB2*    rs200787930   C/T        \<0.0001    0.01         0.01-0.10                                  \<0.0001   0.01   0.01-0.10                     
  *CXCL8*    rs188378669   G/T        \<0.0001    0.01         0.01-0.10                                  \<0.0001   0.01   0.01-0.10                     
  *MARCH1*   rs61734696    G/T        \<0.0001    0.01         0.01-0.10                                  \<0.0001   0.01   0.01-0.10                     
  *VPS33B*   rs199921354   C/T        \<0.0001    0.01         0.01-0.10                                  \<0.0001   0.01   0.01-0.10                     
  *TMOD4*    rs115287176   G/A        \<0.0001    0.01         0.01-0.11                                  \<0.0001   0.01   0.01-0.11                     
  *COL6A3*   rs146092501   C/T        \<0.0001    0.01         0.01-0.10                                  \<0.0001   0.01   0.01-0.10                     
  *ZNF77*    rs146879198   G/A        \<0.0001    0.01         0.01-0.11                                  \<0.0001   0.01   0.01-0.11                     
  *ADGRL3*   rs192210727   G/T        \<0.0001    0.06         0.02-0.16    0.1736                        \<0.0001   0.06   0.02-0.16   0.9960            
  *ALDH2*    rs671         G/A        \<0.0001    2.00         1.56-2.55    \<0.0001   2.00   1.70-2.36   0.0040     1.46   1.13-1.90   \<0.0001   2.71   2.08-3.53
  *ACAD10*   rs11066015    G/A        \<0.0001    0.51         0.39-0.65    \<0.0001   0.50   0.43-0.59   0.0049     0.69   0.53-0.89   \<0.0001   0.37   0.29-0.49
  *BRAP*     rs3782886     A/G        \<0.0001    1.98         1.67-2.34    \<0.0001   1.88   1.48-2.39   \<0.0001   1.84   1.55-2.20   \<0.0001   2.58   1.99-3.35
  *HECTD4*   rs11066280    T/A        \<0.0001    2.02         1.71-2.38    \<0.0001   1.92   1.51-2.45   \<0.0001   1.88   1.58-2.24   \<0.0001   2.66   2.05-3.46
  *HECTD4*   rs2074356     C/T        \<0.0001    1.85         1.57-2.17    \<0.0001   1.92   1.47-2.51   \<0.0001   1.73   1.46-2.06   \<0.0001   2.48   1.87-3.28
  *OR52E4*   rs11823828    T/G        \<0.0001    1.56         1.30-1.87    \<0.0001   2.16   1.74-2.68   0.0152     1.28   1.05-1.56   \<0.0001   2.46   1.93-3.13
             rs12229654    T/G        \<0.0001    1.64         1.39-1.92    \<0.0001   1.89   1.41-2.53   \<0.0001   1.54   1.30-1.82   \<0.0001   2.27   1.67-3.07
  *NAA25*    rs12231744    C/T        \<0.0001    0.60         0.51-0.71    \<0.0001   0.49   0.37-0.64   \<0.0001   0.67   0.56-0.79   \<0.0001   0.40   0.30-0.53
  *ATXN2*    rs7969300     T/C        \<0.0001    0.59         0.50-0.70    \<0.0001   0.55   0.43-0.71   \<0.0001   0.65   0.55-0.77   \<0.0001   0.44   0.34-0.57
  *GOSR2*    rs1052586     T/C        0.0002      0.71         0.59-0.85    \<0.0001   0.61   0.50-0.75   0.0236     0.80   0.66-0.97   \<0.0001   0.53   0.42-0.67
  *TCHP*     rs74416240    G/A        \<0.0001    1.46         1.23-1.73    0.2849                        \<0.0001   1.46   1.22-1.74   0.1399            
  *GIT2*     rs925368      A/G        \<0.0001    1.48         1.24-1.76    0.5500                        \<0.0001   1.49   1.25-1.79   0.3309            
             rs2523644     A/G        \<0.0001    1.74         1.41-2.14    0.5858                        \<0.0001   1.76   1.42-2.17   0.4407            
  *OAS3*     rs2072134     C/T        \<0.0001    1.45         1.23-1.71    0.0408     1.51   1.02-2.25   \<0.0001   1.42   1.20-1.69   0.0093     1.71   1.14-2.55
  *CCDC63*   rs10774610    T/C        \<0.0001    1.38         1.18-1.62    0.0085     1.49   1.11-2.01   0.0009     1.33   1.12-1.58   0.0009     1.68   1.24-2.29
             rs2596548     G/T        \<0.0001    1.95         1.53-2.48    0.3820                        \<0.0001   2.04   1.60-2.61   0.4739            
  *CCDC63*   rs10849915    T/C        \<0.0001    1.38         1.18-1.63    0.0184     1.44   1.06-1.94   0.0006     1.34   1.14-1.59   0.0021     1.63   1.19-2.22

Multivariable logistic regression analysis was performed with adjustment for age, sex, and the prevalence of hypertension, diabetes mellitus, and dyslipidemia. Based on Bonferroni\'s correction, P\<0.0005 (0.05/100) was considered statistically significant. SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval.

###### 

Association between SNPs and hypertension as determined by multivariable logistic regression analysis.

  Gene        SNP           Dominant   Recessive   Additive 1   Additive 2                                                                
  ----------- ------------- ---------- ----------- ------------ ------------ -------- -- -- ---------- ------ ----------- -------- ------ -----------
  *MARCH1*    rs61734696    G/T        0.0002      0.62         0.48-0.79                   0.0002     0.62   0.48-0.79                   
  *PLCB2*     rs200787930   C/T        0.0003      0.63         0.49-0.81                   0.0003     0.63   0.49-0.81                   
  *COL6A3*    rs146092501   C/T        0.0002      0.61         0.47-0.79                   0.0002     0.61   0.47-0.79                   
  *COL6A5*    rs200982668   G/A        0.0005      0.65         0.50-0.83                   0.0005     0.65   0.50-0.83                   
  *MOB3C*     rs139537100   C/T        0.0006      0.64         0.50-0.83                   0.0006     0.64   0.50-0.83                   
  *VPS33B*    rs199921354   C/T        0.0003      0.63         0.49-0.81                   0.0003     0.63   0.49-0.81                   
  *NCR3*      rs2515920     T/A        \<0.0001    0.74         0.67-0.82    0.0930         \<0.0001   0.74   0.66-0.82   0.0226   0.72   0.54-0.95
  *TMOD4*     rs115287176   G/A        0.0004      0.63         0.49-0.81                   0.0004     0.63   0.49-0.81                   
  *CXCL8*     rs188378669   G/T        0.0004      0.63         0.49-0.81                   0.0004     0.63   0.49-0.81                   
              rs769177      G/A        \<0.0001    0.74         0.67-0.82    0.0946         \<0.0001   0.74   0.67-0.83   0.0238   0.72   0.54-0.96
  *NFKBIL1*   rs2071593     C/T        \<0.0001    0.74         0.67-0.82    0.2491         \<0.0001   0.74   0.67-0.82   0.0628          

Multivariable logistic regression analysis was performed with adjustment for age and sex. Based on Bonferroni\'s correction, P\<0.0011 (0.05/44) was considered statistically significant. SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval.

###### 

Association between SNPs and chronic kidney disease as determined by multivariable logistic regression analysis.

  Gene       SNP           Dominant   Recessive   Additive 1   Additive 2                                                          
  ---------- ------------- ---------- ----------- ------------ ------------ -------- -- -- -------- ------ ----------- -------- -- --
  *COL6A5*   rs200982668   G/A        0.0002      0.25         0.12-0.52                   0.0002   0.25   0.12-0.52               
  *MARCH1*   rs61734696    G/T        0.0004      0.26         0.12-0.55                   0.0004   0.26   0.12-0.55               
  *MUC17*    rs78010183    A/T        0.0008      0.35         0.19-0.65                   0.0008   0.35   0.19-0.65               
  *MOB3C*    rs139537100   C/T        0.0006      0.27         0.13-0.57                   0.0006   0.27   0.13-0.57               
  *PLCB2*    rs200787930   C/T        0.0007      0.27         0.13-0.57                   0.0007   0.27   0.13-0.57               
  *CXCL8*    rs188378669   G/T        0.0004      0.26         0.12-0.55                   0.0004   0.26   0.12-0.55               
  *VPS33B*   rs199921354   C/T        0.0007      0.27         0.13-0.58                   0.0007   0.27   0.13-0.58               
  *TMOD4*    rs115287176   G/A        0.0007      0.27         0.13-0.58                   0.0007   0.27   0.13-0.58               
  *ADGRL3*   rs192210727   G/T        0.0006      0.27         0.12-0.57    0.4876         0.0007   0.27   0.13-0.57   0.9964      
  *ZNF77*    rs146879198   G/A        0.0009      0.28         0.13-0.59                   0.0009   0.28   0.13-0.59               
  *COL6A3*   rs146092501   C/T        0.0010      0.28         0.13-0.60                   0.0010   0.28   0.13-0.60               

Multivariable logistic regression analysis was performed with adjustment for age, sex, and the prevalence of hypertension and diabetes mellitus. Based on Bonferroni\'s correction, P\<0.0011 (0.05/44) was considered statistically significant. SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval.

###### 

Association between SNPs associated with myocardial infarction and intermediate phenotypes.

  Gene       SNP             Hypertension   DM           Hyper-TG       Hypo-HDL     Hyper-LDL      CKD            Obesity        Hyperuricemia   
  ---------- --------------- -------------- ------------ -------------- ------------ -------------- -------------- -------------- --------------- --------------
  *PLCB2*    rs200787930     C/T            0.0004       0.0026         0.5013       **\<0.0001**   **\<0.0001**   **\<0.0001**   0.0482          0.7764
  *CXCL8*    rs188378669     G/T            0.0007       0.0039         0.8922       **\<0.0001**   **\<0.0001**   **\<0.0001**   0.0259          0.9412
  *MARCH1*   rs61734696      G/T            **0.0002**   0.0013         0.5876       **\<0.0001**   **\<0.0001**   **\<0.0001**   0.0381          0.7835
  *VPS33B*   rs199921354     C/T            0.0006       0.0026         0.5939       **\<0.0001**   **\<0.0001**   **\<0.0001**   0.0398          0.9038
  *TMOD4*    rs115287176     G/A            0.0006       0.0073         0.9087       **\<0.0001**   **\<0.0001**   **\<0.0001**   0.0578          0.8457
  *COL6A3*   rs146092501 C   /T             0.0004       0.0058         0.8385       **\<0.0001**   **\<0.0001**   **\<0.0001**   0.0459          0.8305
  *ZNF77*    rs146879198     G/A            0.0014       0.0053         0.8625       **\<0.0001**   **\<0.0001**   **\<0.0001**   0.0245          0.9643
  *ADGRL3*   rs192210727     G/T            0.0106       0.0262         0.6918       **\<0.0001**   **\<0.0001**   **\<0.0001**   0.0501          0.5669
  *ALDH2*    rs671           G/A            0.0017       0.0231         0.0253       **\<0.0001**   **0.0002**     0.0297         0.0479          **\<0.0001**
  *ACAD10*   rs11066015      G/A            0.0014       0.0300         0.0261       **\<0.0001**   **0.0002**     0.0376         0.0578          **\<0.0001**
  *BRAP*     rs3782886       A/G            0.0012       0.0675         0.0233       **\<0.0001**   0.0008         0.0329         0.0548          **\<0.0001**
  *HECTD4*   rs11066280      T/A            0.0052       0.2161         0.0093       **\<0.0001**   **0.0002**     0.0172         0.1293          **\<0.0001**
  *HECTD4*   rs2074356       C/T            0.0245       0.2148         0.0042       **\<0.0001**   **0.0003**     0.0218         0.2238          **\<0.0001**
  *OR52E4*   rs11823828      T/G            0.0429       **\<0.0001**   0.0917       0.2341         0.8312         0.0161         0.0768          0.1053
             rs12229654      T/G            0.0200       0.4309         0.0996       **\<0.0001**   0.0290         0.0633         0.2134          **\<0.0001**
  *NAA25*    rs12231744      C/T            0.0913       0.5214         0.0151       **0.0002**     0.2175         0.8586         0.3543          0.0055
  *ATXN2*    rs7969300       T/C            0.0368       0.6341         **0.0001**   0.0005         0.7189         0.3631         0.3155          0.0047
  *GOSR2*    rs1052586       T/C            0.5175       0.0843         0.3162       0.0718         0.1779         0.6525         0.4307          0.5766
  *TCHP*     rs74416240      G/A            0.4244       0.0279         0.0630       0.0594         0.0142         0.0037         0.3409          0.1148
  *GIT2*     rs925368        A/G            0.3492       0.0515         0.0337       0.0873         0.0105         0.0020         0.4399          0.0998
             rs2523644       A/G            0.4464       0.2581         0.5651       0.0797         0.0674         0.0397         0.4203          0.3215
  *OAS3*     rs2072134       C/T            0.6477       0.0936         0.1902       0.0004         0.0030         0.1862         0.2580          0.0185
  *CCDC63*   rs10774610      T/C            0.3573       0.2133         0.2623       0.0030         0.0102         0.0055         0.5909          **\<0.0001**
             rs2596548       G/T            0.2749       0.0268         0.2615       0.2138         0.3223         0.0751         0.9065          0.2475
  *CCDC63*   rs10849915      T/C            0.3386       0.2256         0.2891       0.0025         0.0135         0.0060         0.5869          **\<0.0001**

Data are P-values. The association between genotypes of each SNP and intermediate phenotypes was examined with Pearson\'s χ^2^ test. Based on Bonferroni\'s correction, P\<0.0003 (0.05/200) were considered statistically significant and are shown in bold. SNP, single nucleotide polymorphism; DM, diabetes mellitus; hyper-TG, hypertriglyceridemia; hypo-HDL, hypo-high density lipoprotein-cholesterolemia; hyper-LDL, hyper-low density lipoprotein-cholesterolemia; CKD, chronic kidney disease.

###### 

Association between SNPs associated with hypertension and systolic or diastolic BP.

  Gene        SNP                   Systolic BP (mmHg)   P-value   Diastolic BP (mmHg)   P-value                                
  ----------- --------------- ----- -------------------- --------- --------------------- -------------- ------- ------- ------- ------------
  *MARCH1*    rs61734696      G/T   *GG*                 *GT*                            **\<0.0001**   *GG*    *GT*            0.0239
                                    128±24               119±16                                         77±14   75±12           
  *PLCB2*     rs200787930 C   /T    *CC*                 *CT*                            **\<0.0001**   *CC*    *CT*            0.0482
                                    128±24               119±16                                         77±14   75±12           
  *COL6A3*    rs146092501 C   /T    *CC*                 *CT*                            **\<0.0001**   *CC*    *CT*            0.0584
                                    128±24               119±15                                         77±14   75±12           
  *COL6A5*    rs200982668     G/A   *GG*                 *GA*                            **\<0.0001**   *GG*    *GA*            0.0341
                                    128±24               119±16                                         77±14   75±12           
  *MOB3C*     rs139537100 C   /T    *CC*                 *CT*                            **\<0.0001**   *CC*    *CT*            0.0359
                                    128±24               119±16                                         77±14   75±12           
  *VPS33B*    rs199921354 C   /T    *CC*                 *CT*                            **\<0.0001**   *CC*    *CT*            0.0348
                                    128±24               119±16                                         77±14   75±12           
  *NCR3*      rs2515920       T/A   *TT*                 *TA*      *AA*                  **\<0.0001**   *TT*    *TA*    *AA*    0.0062
                                    128±24               125±22    126±23                               77±14   76±13   76±13   
  *TMOD4*     rs115287176     G/A   *GG*                 *GA*                            **\<0.0001**   *GG*    *GA*            0.0793
                                    128±24               119±16                                         77±14   75±12           
  *CXCL8*     rs188378669     G/T   *GG*                 *GT*                            **\<0.0001**   *GG*    *GT*            0.0703
                                    128±24               119±16                                         77±14   75±12           
              rs769177        G/A   *GG*                 *GA*      *AA*                  **0.0001**     *GG*    *GA*    *AA*    0.0094
                                    128±24               125±22    126±23                               77±14   76±13   76±13   
  *NFKBIL1*   rs2071593       C/T   *CC*                 *CT*      *TT*                  **\<0.0001**   *CC*    *CT*    *TT*    **0.0012**
                                    128±24               125±22    127±23                               77±14   76±13   76±13   

Data are presented as the mean ± standard deviation and were compared among genotypes by one-way analysis of variance. Based on Bonferroni\'s correction, P\<0.0023 (0.05/22) was considered statistically significant and are shown in bold. SNP, single nucleotide polymorphism; BP, blood pressure.

###### 

Association between SNPs associated with chronic kidney disease and the serum concentration of creatinine and eGFR.

  Gene       SNP                   Serum creatinine (µmol/l)   P-value     eGFR (ml min^−1^ 1.73 m^−2^)   P-value                                  
  ---------- --------------- ----- --------------------------- ----------- ------------------------------ --------- ----------- ----------- ------ --------------
  *COL6A5*   rs200982668     G/A   *GG*                        *GA*                                       0.0281    *GG*        *GA*               **\<0.0001**
                                   93.6±138.5                  61.8±34.4                                            79.3±32.9   95.2±20.2          
  *MARCH1*   rs61734696      G/T   *GG*                        *GT*                                       0.0352    *GG*        *GT*               **\<0.0001**
                                   93.5±138.3                  62.4±35.0                                            79.3±32.9   94.7±20.3          
  *MUC17*    rs78010183      A/T   *AA*                        *AT*                                       0.0068    *AA*        *AT*               **\<0.0001**
                                   93.8±139.0                  59.2±18.8                                            79.4±33.0   93.0±19.9          
  *MOB3C*    rs139537100 C   /T    *CC*                        *CT*                                       0.0374    *CC*        *CT*               **\<0.0001**
                                   93.5±138.4                  62.4±35.5                                            79.3±32.9   94.9±20.8          
  *PLCB2*    rs200787930 C   /T    *CC*                        *CT*                                       0.0380    *CC*        *CT*               **\<0.0001**
                                   93.5±138.3                  62.5±35.4                                            79.3±32.9   94.8±20.8          
  *CXCL8*    rs188378669     G/T   *GG*                        *GT*                                       0.0397    *GG*        *GT*               **\<0.0001**
                                   93.5±138.3                  62.6±35.6                                            79.3±32.9   95.0±20.9          
  *VPS33B*   rs199921354 C   /T    *CC*                        *CT*                                       0.0406    *CC*        *CT*               **\<0.0001**
                                   93.5±138.4                  62.6±35.8                                            79.3±32.9   94.8±21.1          
  *TMOD4*    rs115287176     G/A   *GG*                        *GA*                                       0.0426    *GG*        *GA*               **\<0.0001**
                                   93.4±138.2                  62.8±35.8                                            79.4±32.9   94.6±20.9          
  *ADGRL3*   rs192210727     G/T   *GG*                        *GT*        *TT*                           0.1294    *GG*        *GT*        *TT*   **0.0002**
                                   93.2±137.5                  63.0±35.8   64.5                                     79.3±32.9   94.4±21.4   94.3   
  *ZNF77*    rs146879198     G/A   *GG*                        *GA*                                       0.0491    *GG*        *GA*               **\<0.0001**
                                   93.4±138.1                  63.1±36.4                                            79.4±32.9   94.3±21.1          
  *COL6A3*   rs146092501 C   /T    *CC*                        *CT*                                       0.0466    *CC*        *CT*               **\<0.0001**
                                   93.4±138.2                  62.8±36.4                                            79.4±32.9   94.6±21.2          

Data are presented as the mean ± standard deviation and were compared among genotypes by one-way analysis of variance. Based on Bonferroni\'s correction, P\<0.0023 (0.05/22) was considered statistically significant and are shown in bold. SNP, single nucleotide polymorphism; eGFR, estimated glomerular filtration rate.

###### 

Association between genes, chromosomal loci, and SNPs associated with MI in the present study and previously examined cardiovascular disease-related phenotypes.

  Gene/chr. locus   SNP           Chr.   Position    Previously examined phenotypes
  ----------------- ------------- ------ ----------- -----------------------------------------------------------------------------------------------------
  *TMOD4*           rs115287176   1      151170961   None
  *COL6A3*          rs146092501   2      237371861   None
  *ADGRL3*          rs192210727   4      61909615    None
  *CXCL8*           rs188378669   4      73741568    Total cholesterol (23063622)
  *MARCH1*          rs61734696    4      164197303   Adiponectin concentrations (20887962)
  6p21.3            rs2596548     6      31362769    MI (21971053)
                    rs2523644            31374707    
  *OR52E4*          rs11823828    11     5884973     None
  *TCHP*            rs74416240    12     109904793   None
  *GIT2*            rs925368      12     109953174   None
  *CCDC63*          rs10849915    12     110895818   None
                    rs10774610           110902439   
  12q24.1           rs12229654    12     110976657   HDL-cholesterol (21909109)
  *ATXN2*           rs7969300     12     111555908   MI (19820697, 19198610), CAD (19820697, 23202125, 21060863)
  *BRAP*            rs3782886     12     111672685   MI (21971053, 19820697, 21107343), CAD (21971053, 21572416, 23202125, 19820697, 23364394, 21060863)
  *ACAD10*          rs11066015    12     111730205   CAD (23364394, 23202125)
  *ALDH2*           rs671         12     111803962   MI (21971053), CAD (21971053, 21572416, 23202125)
  *NAA25*           rs12231744    12     112039251   MI (19820697, 23202125), CAD (21971053, 19820697)
  *HECTD4*          rs2074356     12     112207597   MI (19820697), CAD (21971053, 21572416, 22751097, 19820697, 23364394, 23202125)
                    rs11066280           112379979   
  *OAS3*            rs2072134     12     112971371   HDL-cholesterol (21909109)
  *PLCB2*           rs200787930   15     40289298    Triglycerides (23063622)
  *VPS33B*          rs199921354   15     91013841    Type 2 diabetes (22885922)
  *GOSR2*           rs1052586     17     46941097    Systolic BP (21909110, 21909115)
  *ZNF77*           rs146879198   19     2934109     None

Data were obtained from the Genome-Wide Repository of Associations Between SNPs and Phenotypes Search database (<https://grasp.nhlbi.nih.gov/Search.aspx>) with P\<1.0×10^−6^. Numbers in parentheses are PubMed IDs. SNP, single nucleotide polymorphism; MI, myocardial infarction; Chr., chromosome; HDL, high density lipoprotein; CAD, coronary artery disease; BP, blood pressure.

###### 

Association between genes, chromosomal loci, and SNPs associated with hypertension in the present study and previously examined cardiovascular disease-related phenotypes.

  Gene/chr. locus   SNP           Chr.   Position    Previously examined phenotypes
  ----------------- ------------- ------ ----------- ------------------------------------------------------------------------
  *MOB3C*           rs139537100   1      46615006    None
  *TMOD4*           rs115287176   1      151170961   None
  *COL6A3*          rs146092501   2      237371861   None
  *COL6A5*          rs200982668   3      130470894   None
  *CXCL8*           rs188378669   4      73741568    Total cholesterol (23063622)
  *MARCH1*          rs61734696    4      164197303   Adiponectin concentrations (20887962)
  *NFKBIL1*         rs2071593     6      31545022    Total cholesterol (20686565)
  6p21.3            rs769177      6      31579834    Total cholesterol (20686565), triglycerides (20686565), CAD (21971053)
  *NCR3*            rs2515920     6      31594838    Total cholesterol (20686565)
  *PLCB2*           rs200787930   15     40289298    Triglycerides (23063622)
  *VPS33B*          rs199921354   15     91013841    Type 2 diabetes (22885922)

Data were obtained from the Genome-Wide Repository of Associations Between SNPs and Phenotypes Search database (<https://grasp.nhlbi.nih.gov/Search.aspx>) with a P\<1.0×10^−6^. Numbers in parentheses are PubMed IDs. SNP, single nucleotide polymorphism; Chr., chromosome; CAD, coronary artery disease.

###### 

Association between genes and SNPs associated with chronic kidney disease in the present study and previously examined cardiovascular and renal phenotypes.

  Gene       SNP           Chr.   Position    Previously examined phenotypes
  ---------- ------------- ------ ----------- ---------------------------------------
  *MOB3C*    rs139537100   1      46615006    None
  *TMOD4*    rs115287176   1      151170961   None
  *COL6A3*   rs146092501   2      237371861   None
  *COL6A5*   rs200982668   3      130470894   None
  *ADGRL3*   rs192210727   4      61909615    None
  *CXCL8*    rs188378669   4      73741568    Total cholesterol (23063622)
  *MARCH1*   rs61734696    4      164197303   Adiponectin concentrations (20887962)
  *MUC17*    rs78010183    7      101035329   None
  *PLCB2*    rs200787930   15     40289298    Triglycerides (23063622)
  *VPS33B*   rs199921354   15     91013841    Type 2 diabetes (22885922)
  *ZNF77*    rs146879198   19     2934109     None

Data were obtained from the Genome-Wide Repository of Associations Between SNPs and Phenotypes Search database (<https://grasp.nhlbi.nih.gov/Search.aspx>) with a P\<1.0×10^−6^. Numbers in parentheses are PubMed IDs. SNP, single nucleotide polymorphism; Chr., chromosome.

###### 

Gene Ontology analysis of the 18 genes identified in the present study.

  Gene        Function                                                                                                                                                          Biological process
  ----------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *MOB3C*     Protein binding, metal ion binding                                                                                                                                Uncharacterized
  *TMOD4*     Actin binding, tropomyosin binding                                                                                                                                Muscle contraction, actin filament organization, myofibril assembly, pointed-end actin filament capping
  *COL6A3*    Serine-type endopeptidase inhibitor activity, extracellular matrix structural constituent conferring tensile strength, collagen-containing extracellular matrix   Cell adhesion, muscle organ development, negative regulation of endopeptidase activity, extracellular matrix organization
  *ADGRL3*    G protein-coupled receptor activity, calcium ion binding, protein binding, carbohydrate binding                                                                   Neuron migration, signal transduction, G protein-coupled receptor signaling pathway, positive regulation of synapse assembly, cell-cell adhesion via plasma-membrane adhesion molecules
  *CXCL8*     Cytokine activity, interleukin-8 receptor binding, protein binding                                                                                                Positive regulation of angiogenesis, induction of positive chemotaxis, defense response, inflammatory response, immune response, cell cycle arrest, negative regulation of G protein-coupled receptor protein signaling pathway, negative regulation of cell proliferation, cytokine-mediated signaling pathway, calcium-mediated signaling, regulation of cell adhesion, positive regulation of neutrophil chemotaxis, receptor internalization, response to endoplasmic reticulum stress, intracellular signal transduction, PKR-like endoplasmic reticulum kinase-mediated unfolded protein response, neutrophil activation, cellular responses to fibroblast growth factor stimulus, lipopolysaccharide, interleukin-1, and tumor necrosis factor
  *MARCH1*    Ubiquitin-protein transferase activity, zinc ion binding, MHC protein binding, ubiquitin protein ligase activity                                                  Protein polyubiquitination, immune response, antigen processing and presentation of peptide antigen via MHC class II
  *OR52E4*    G protein-coupled receptor activity, olfactory receptor activity                                                                                                  Signal transduction, G protein-coupled receptor signaling pathway, sensory perception of smell, response to stimulus, detection of chemical stimulus involved in sensory perception of smell
  *TCHP*      Protein binding                                                                                                                                                   Apoptotic process, negative regulation of cell growth, negative regulation of cilium assembly
  *GIT2*      GTPase activator, kinase activity, metal ion binding                                                                                                              Phosphorylation, positive regulation of GTPase activity
  *CCDC63*    Cell differentiation                                                                                                                                              Spermatogenesis, spermatid development, cilium movement, outer dynein arm assembly
  *OAS3*      Nucleotide binding, 2′-5′-oligoadenylate synthetase activity, RNA binding, protein binding, ATP binding, nucleotidyltransferase activity, metal ion binding       Immune response, nucleobase-containing compound metabolic process, defense response to virus, negative regulation of viral genome replication, interferon-g-mediated signaling pathway, regulation of ribonuclease activity
  *PLCB2*     Phosphatidylinositol phospholipase C activity, calcium ion binding, phosphoric diester hydrolase activity                                                         Phospholipid metabolic process, intracellular signal transduction, G protein-coupled receptor signaling pathway, activation of phospholipase C activity, Wnt signaling pathway, calcium-modulating pathway, inositol phosphate metabolic process
  *VPS33B*    Protein binding, AP-3 adaptor complex, clathrin complex                                                                                                           Vesicle docking involved in exocytosis, endosome organization, protein transport, vesicle-mediated transport, peptidyllysine hydroxylation, melanosome localization, lysosome localization, collagen metabolic process, membrane fusion, platelet a granule organization
  *ZNF77*     RNA polymerase II transcription factor activity, sequence-specific DNA binding, metal ion binding                                                                 Regulation of DNA-templated transcription, regulation of transcription by RNA polymerase II
  *COL6A5*    Collagen-containing extracellular matrix, protein binding, extracellular matrix structural constituent conferring tensile strength                                Cell adhesion
  *NFKBIL1*   Protein binding                                                                                                                                                   Inhibitor of NF-κB kinase/NF-κB signaling, cytoplasmic sequestering of transcription factor, negative regulation of lipopolysaccharide-mediated signaling pathway, NF-κB transcription factor activity, tumor necrosis factor production, Toll-like receptor signaling pathway
  *NCR3*      Signaling receptor binding, protein binding, protein homodimerization activity, cell adhesion molecule binding                                                    Regulation of immune response, homophilic and heterophilic cell-cell adhesion via plasma-membrane adhesion molecules, cell recognition, positive regulation of natural killer cell-mediated cytotoxicity, susceptibility to natural killer cell-mediated cytotoxicity and T cell-mediated cytotoxicity
  *MUC17*     Protein binding, PDZ domain binding, extracellular matrix constituent, lubricant activity                                                                         Stimulatory C-type lectin receptor signaling pathway, O-glycan processing, cellular homeostasis

Data for predicted functions and biological processes for the genes were obtained from the database of Gene Ontology and GO Annotations (QuickGO; <https://www.ebi.ac.uk/QuickGO>). GO, Gene Ontology; MHC, major histocompatibility complex; NF-κB, nuclear factor-κB.
